Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions
To cite this article: Vultaggio A, Matucci A, Nencini F, Pratesi S, Parronchi P, Rossi O, Romagnani S, Maggi E. Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions. Allergy 2010; 65: 657-661. Infliximab is a chimeric monoclonal antibody against...
Gespeichert in:
| Veröffentlicht in: | Allergy (Copenhagen) 2010-05, Vol.65 (5), p.657-661 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 661 |
|---|---|
| container_issue | 5 |
| container_start_page | 657 |
| container_title | Allergy (Copenhagen) |
| container_volume | 65 |
| creator | Vultaggio, A Matucci, A Nencini, F Pratesi, S Parronchi, P Rossi, O Romagnani, S Maggi, E |
| description | To cite this article: Vultaggio A, Matucci A, Nencini F, Pratesi S, Parronchi P, Rossi O, Romagnani S, Maggi E. Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions. Allergy 2010; 65: 657-661. Infliximab is a chimeric monoclonal antibody against TNF-α useful in the treatment of many chronic inflammatory diseases. Severe anaphylaxis has been reported during therapy, although the exact mechanism has not been fully defined. The reactions have been related to the infliximab immunogenicity and development of specific antibodies. Evaluation of the development of IgE and non-IgE antibodies to infliximab and their relationship with infusion reaction. Seventy-one patients (11 reactives, 11 therapeutically nonresponders, and 49 unreactive therapeutically responders) and 20 non-infliximab-exposed control subjects (ten rheumatoid arthritis, five spondyloarthropathies, five vasculitis) were evaluated for the presence of IgE (ImmunoCAP assay), IgM, and non-isotype-specific (ELISA assays) anti-infliximab antibodies. Sera were obtained at baseline and during the course of treatment, before each infliximab infusion. Eleven out of 71 patients had a hypersensitivity reaction to infliximab. Non-isotype-specific anti-infliximab antibodies were detected in eight reactive and two nonresponder patients. Three patients with severe reactions displayed anti-infliximab IgE antibodies and positive skin testing. Detectable levels of anti-infliximab IgM antibodies were shown in three additional IgE- and skin testing-negative patients. IgE and IgM antibodies to infliximab were not detectable in the two nonresponder patients. Antibodies developed before the 2nd and the 3rd infusion, and their appearance was strictly related to the timing of the reaction. This report indicates that in some patients with infliximab-related severe reactions, IgE or IgM antibodies against infliximab were detectable. The majority of reactions could be predicted by the appearance of anti-infliximab antibodies. |
| doi_str_mv | 10.1111/j.1398-9995.2009.02280.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_746271865</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2004716031</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4810-83a4c43c9904984bc41bce83034caee3668c1b5973a69b463448f4fc08c1b2773</originalsourceid><addsrcrecordid>eNqNkU1v3CAQhlHVqNmk_QutVanKyS5fxnDoYRUlbaSVemhzRhhDiuWFLdjp7r8PXq9SqZeGC8PM8w4DLwAFghXK63NfISJ4KYSoKwyhqCDGHFb7V2D1XHgNVhDBuqQ14efgIqUeQthgAd-Ac5TriDT1CvRrP7rSeTu4vduqtrh7uCmU7woffLnEo2tD50w6pp3vJj264Itg88FOKcdlNIMaTVck82iiyaDa_ToMKoO6iEYdBektOLNqSObdab8E97c3P6-_lZvvX--u15tSU45gyYmimhItBKSC01ZT1GrDCSRUK2MIY1yjthYNUUy0lBFKuaVWwzmNm4Zcgqul7y6G35NJo9y6pM0wKG_ClGRDGW4QZ_X_SUIEIpDRTH78h-zDFH1-hkSC5UlZzTLEF0jHkFI0Vu5i_tN4kAjK2TfZy9keOdsjZ9_k0Te5z9L3p_5TuzXdX-HJqAx8OgEqaTXYqLx26ZnDuKk5QTxzXxbujxvM4cUDyPVmM0dZ_2HRWxWkeoj5jvsfGOZfQByjhmLyBGJPu6M</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>196904656</pqid></control><display><type>article</type><title>Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Wiley Online Library Free Content</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Vultaggio, A ; Matucci, A ; Nencini, F ; Pratesi, S ; Parronchi, P ; Rossi, O ; Romagnani, S ; Maggi, E</creator><creatorcontrib>Vultaggio, A ; Matucci, A ; Nencini, F ; Pratesi, S ; Parronchi, P ; Rossi, O ; Romagnani, S ; Maggi, E</creatorcontrib><description>To cite this article: Vultaggio A, Matucci A, Nencini F, Pratesi S, Parronchi P, Rossi O, Romagnani S, Maggi E. Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions. Allergy 2010; 65: 657-661. Infliximab is a chimeric monoclonal antibody against TNF-α useful in the treatment of many chronic inflammatory diseases. Severe anaphylaxis has been reported during therapy, although the exact mechanism has not been fully defined. The reactions have been related to the infliximab immunogenicity and development of specific antibodies. Evaluation of the development of IgE and non-IgE antibodies to infliximab and their relationship with infusion reaction. Seventy-one patients (11 reactives, 11 therapeutically nonresponders, and 49 unreactive therapeutically responders) and 20 non-infliximab-exposed control subjects (ten rheumatoid arthritis, five spondyloarthropathies, five vasculitis) were evaluated for the presence of IgE (ImmunoCAP assay), IgM, and non-isotype-specific (ELISA assays) anti-infliximab antibodies. Sera were obtained at baseline and during the course of treatment, before each infliximab infusion. Eleven out of 71 patients had a hypersensitivity reaction to infliximab. Non-isotype-specific anti-infliximab antibodies were detected in eight reactive and two nonresponder patients. Three patients with severe reactions displayed anti-infliximab IgE antibodies and positive skin testing. Detectable levels of anti-infliximab IgM antibodies were shown in three additional IgE- and skin testing-negative patients. IgE and IgM antibodies to infliximab were not detectable in the two nonresponder patients. Antibodies developed before the 2nd and the 3rd infusion, and their appearance was strictly related to the timing of the reaction. This report indicates that in some patients with infliximab-related severe reactions, IgE or IgM antibodies against infliximab were detectable. The majority of reactions could be predicted by the appearance of anti-infliximab antibodies.</description><identifier>ISSN: 0105-4538</identifier><identifier>EISSN: 1398-9995</identifier><identifier>DOI: 10.1111/j.1398-9995.2009.02280.x</identifier><identifier>PMID: 19951375</identifier><identifier>CODEN: LLRGDY</identifier><language>eng</language><publisher>Oxford, UK: Oxford, UK : Blackwell Publishing Ltd</publisher><subject>Adult ; Allergies ; anaphylaxis ; Anaphylaxis - blood ; Anaphylaxis - chemically induced ; Anaphylaxis - immunology ; Anti-Inflammatory Agents - adverse effects ; anti-infliximab antibodies ; Antibodies, Anti-Idiotypic - blood ; Antibodies, Anti-Idiotypic - immunology ; Antibodies, Monoclonal - adverse effects ; Biological and medical sciences ; Dermatology ; drug allergy ; Drug Hypersensitivity - blood ; Drug Hypersensitivity - immunology ; drug-specific IgE and IgM ; Enzyme-Linked Immunosorbent Assay ; Female ; Fundamental and applied biological sciences. Psychology ; Fundamental immunology ; Humans ; Immunoglobulin E - blood ; Immunoglobulin E - immunology ; Immunoglobulin M - blood ; Immunoglobulin M - immunology ; Immunoglobulins ; Infliximab ; Male ; Medical sciences ; Middle Aged ; Monoclonal antibodies ; Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis ; Skin Tests</subject><ispartof>Allergy (Copenhagen), 2010-05, Vol.65 (5), p.657-661</ispartof><rights>2009 John Wiley & Sons A/S</rights><rights>2015 INIST-CNRS</rights><rights>Journal compilation © 2010 John Wiley & Sons A/S</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4810-83a4c43c9904984bc41bce83034caee3668c1b5973a69b463448f4fc08c1b2773</citedby><cites>FETCH-LOGICAL-c4810-83a4c43c9904984bc41bce83034caee3668c1b5973a69b463448f4fc08c1b2773</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1398-9995.2009.02280.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1398-9995.2009.02280.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,1427,27901,27902,45550,45551,46384,46808</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=22758318$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19951375$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Vultaggio, A</creatorcontrib><creatorcontrib>Matucci, A</creatorcontrib><creatorcontrib>Nencini, F</creatorcontrib><creatorcontrib>Pratesi, S</creatorcontrib><creatorcontrib>Parronchi, P</creatorcontrib><creatorcontrib>Rossi, O</creatorcontrib><creatorcontrib>Romagnani, S</creatorcontrib><creatorcontrib>Maggi, E</creatorcontrib><title>Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions</title><title>Allergy (Copenhagen)</title><addtitle>Allergy</addtitle><description>To cite this article: Vultaggio A, Matucci A, Nencini F, Pratesi S, Parronchi P, Rossi O, Romagnani S, Maggi E. Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions. Allergy 2010; 65: 657-661. Infliximab is a chimeric monoclonal antibody against TNF-α useful in the treatment of many chronic inflammatory diseases. Severe anaphylaxis has been reported during therapy, although the exact mechanism has not been fully defined. The reactions have been related to the infliximab immunogenicity and development of specific antibodies. Evaluation of the development of IgE and non-IgE antibodies to infliximab and their relationship with infusion reaction. Seventy-one patients (11 reactives, 11 therapeutically nonresponders, and 49 unreactive therapeutically responders) and 20 non-infliximab-exposed control subjects (ten rheumatoid arthritis, five spondyloarthropathies, five vasculitis) were evaluated for the presence of IgE (ImmunoCAP assay), IgM, and non-isotype-specific (ELISA assays) anti-infliximab antibodies. Sera were obtained at baseline and during the course of treatment, before each infliximab infusion. Eleven out of 71 patients had a hypersensitivity reaction to infliximab. Non-isotype-specific anti-infliximab antibodies were detected in eight reactive and two nonresponder patients. Three patients with severe reactions displayed anti-infliximab IgE antibodies and positive skin testing. Detectable levels of anti-infliximab IgM antibodies were shown in three additional IgE- and skin testing-negative patients. IgE and IgM antibodies to infliximab were not detectable in the two nonresponder patients. Antibodies developed before the 2nd and the 3rd infusion, and their appearance was strictly related to the timing of the reaction. This report indicates that in some patients with infliximab-related severe reactions, IgE or IgM antibodies against infliximab were detectable. The majority of reactions could be predicted by the appearance of anti-infliximab antibodies.</description><subject>Adult</subject><subject>Allergies</subject><subject>anaphylaxis</subject><subject>Anaphylaxis - blood</subject><subject>Anaphylaxis - chemically induced</subject><subject>Anaphylaxis - immunology</subject><subject>Anti-Inflammatory Agents - adverse effects</subject><subject>anti-infliximab antibodies</subject><subject>Antibodies, Anti-Idiotypic - blood</subject><subject>Antibodies, Anti-Idiotypic - immunology</subject><subject>Antibodies, Monoclonal - adverse effects</subject><subject>Biological and medical sciences</subject><subject>Dermatology</subject><subject>drug allergy</subject><subject>Drug Hypersensitivity - blood</subject><subject>Drug Hypersensitivity - immunology</subject><subject>drug-specific IgE and IgM</subject><subject>Enzyme-Linked Immunosorbent Assay</subject><subject>Female</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Fundamental immunology</subject><subject>Humans</subject><subject>Immunoglobulin E - blood</subject><subject>Immunoglobulin E - immunology</subject><subject>Immunoglobulin M - blood</subject><subject>Immunoglobulin M - immunology</subject><subject>Immunoglobulins</subject><subject>Infliximab</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Monoclonal antibodies</subject><subject>Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis</subject><subject>Skin Tests</subject><issn>0105-4538</issn><issn>1398-9995</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkU1v3CAQhlHVqNmk_QutVanKyS5fxnDoYRUlbaSVemhzRhhDiuWFLdjp7r8PXq9SqZeGC8PM8w4DLwAFghXK63NfISJ4KYSoKwyhqCDGHFb7V2D1XHgNVhDBuqQ14efgIqUeQthgAd-Ac5TriDT1CvRrP7rSeTu4vduqtrh7uCmU7woffLnEo2tD50w6pp3vJj264Itg88FOKcdlNIMaTVck82iiyaDa_ToMKoO6iEYdBektOLNqSObdab8E97c3P6-_lZvvX--u15tSU45gyYmimhItBKSC01ZT1GrDCSRUK2MIY1yjthYNUUy0lBFKuaVWwzmNm4Zcgqul7y6G35NJo9y6pM0wKG_ClGRDGW4QZ_X_SUIEIpDRTH78h-zDFH1-hkSC5UlZzTLEF0jHkFI0Vu5i_tN4kAjK2TfZy9keOdsjZ9_k0Te5z9L3p_5TuzXdX-HJqAx8OgEqaTXYqLx26ZnDuKk5QTxzXxbujxvM4cUDyPVmM0dZ_2HRWxWkeoj5jvsfGOZfQByjhmLyBGJPu6M</recordid><startdate>201005</startdate><enddate>201005</enddate><creator>Vultaggio, A</creator><creator>Matucci, A</creator><creator>Nencini, F</creator><creator>Pratesi, S</creator><creator>Parronchi, P</creator><creator>Rossi, O</creator><creator>Romagnani, S</creator><creator>Maggi, E</creator><general>Oxford, UK : Blackwell Publishing Ltd</general><general>Blackwell Publishing Ltd</general><general>Blackwell</general><scope>FBQ</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>201005</creationdate><title>Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions</title><author>Vultaggio, A ; Matucci, A ; Nencini, F ; Pratesi, S ; Parronchi, P ; Rossi, O ; Romagnani, S ; Maggi, E</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4810-83a4c43c9904984bc41bce83034caee3668c1b5973a69b463448f4fc08c1b2773</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Adult</topic><topic>Allergies</topic><topic>anaphylaxis</topic><topic>Anaphylaxis - blood</topic><topic>Anaphylaxis - chemically induced</topic><topic>Anaphylaxis - immunology</topic><topic>Anti-Inflammatory Agents - adverse effects</topic><topic>anti-infliximab antibodies</topic><topic>Antibodies, Anti-Idiotypic - blood</topic><topic>Antibodies, Anti-Idiotypic - immunology</topic><topic>Antibodies, Monoclonal - adverse effects</topic><topic>Biological and medical sciences</topic><topic>Dermatology</topic><topic>drug allergy</topic><topic>Drug Hypersensitivity - blood</topic><topic>Drug Hypersensitivity - immunology</topic><topic>drug-specific IgE and IgM</topic><topic>Enzyme-Linked Immunosorbent Assay</topic><topic>Female</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Fundamental immunology</topic><topic>Humans</topic><topic>Immunoglobulin E - blood</topic><topic>Immunoglobulin E - immunology</topic><topic>Immunoglobulin M - blood</topic><topic>Immunoglobulin M - immunology</topic><topic>Immunoglobulins</topic><topic>Infliximab</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Monoclonal antibodies</topic><topic>Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis</topic><topic>Skin Tests</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Vultaggio, A</creatorcontrib><creatorcontrib>Matucci, A</creatorcontrib><creatorcontrib>Nencini, F</creatorcontrib><creatorcontrib>Pratesi, S</creatorcontrib><creatorcontrib>Parronchi, P</creatorcontrib><creatorcontrib>Rossi, O</creatorcontrib><creatorcontrib>Romagnani, S</creatorcontrib><creatorcontrib>Maggi, E</creatorcontrib><collection>AGRIS</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Allergy (Copenhagen)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Vultaggio, A</au><au>Matucci, A</au><au>Nencini, F</au><au>Pratesi, S</au><au>Parronchi, P</au><au>Rossi, O</au><au>Romagnani, S</au><au>Maggi, E</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions</atitle><jtitle>Allergy (Copenhagen)</jtitle><addtitle>Allergy</addtitle><date>2010-05</date><risdate>2010</risdate><volume>65</volume><issue>5</issue><spage>657</spage><epage>661</epage><pages>657-661</pages><issn>0105-4538</issn><eissn>1398-9995</eissn><coden>LLRGDY</coden><abstract>To cite this article: Vultaggio A, Matucci A, Nencini F, Pratesi S, Parronchi P, Rossi O, Romagnani S, Maggi E. Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions. Allergy 2010; 65: 657-661. Infliximab is a chimeric monoclonal antibody against TNF-α useful in the treatment of many chronic inflammatory diseases. Severe anaphylaxis has been reported during therapy, although the exact mechanism has not been fully defined. The reactions have been related to the infliximab immunogenicity and development of specific antibodies. Evaluation of the development of IgE and non-IgE antibodies to infliximab and their relationship with infusion reaction. Seventy-one patients (11 reactives, 11 therapeutically nonresponders, and 49 unreactive therapeutically responders) and 20 non-infliximab-exposed control subjects (ten rheumatoid arthritis, five spondyloarthropathies, five vasculitis) were evaluated for the presence of IgE (ImmunoCAP assay), IgM, and non-isotype-specific (ELISA assays) anti-infliximab antibodies. Sera were obtained at baseline and during the course of treatment, before each infliximab infusion. Eleven out of 71 patients had a hypersensitivity reaction to infliximab. Non-isotype-specific anti-infliximab antibodies were detected in eight reactive and two nonresponder patients. Three patients with severe reactions displayed anti-infliximab IgE antibodies and positive skin testing. Detectable levels of anti-infliximab IgM antibodies were shown in three additional IgE- and skin testing-negative patients. IgE and IgM antibodies to infliximab were not detectable in the two nonresponder patients. Antibodies developed before the 2nd and the 3rd infusion, and their appearance was strictly related to the timing of the reaction. This report indicates that in some patients with infliximab-related severe reactions, IgE or IgM antibodies against infliximab were detectable. The majority of reactions could be predicted by the appearance of anti-infliximab antibodies.</abstract><cop>Oxford, UK</cop><pub>Oxford, UK : Blackwell Publishing Ltd</pub><pmid>19951375</pmid><doi>10.1111/j.1398-9995.2009.02280.x</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0105-4538 |
| ispartof | Allergy (Copenhagen), 2010-05, Vol.65 (5), p.657-661 |
| issn | 0105-4538 1398-9995 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_746271865 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete; Wiley Online Library Free Content; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Adult Allergies anaphylaxis Anaphylaxis - blood Anaphylaxis - chemically induced Anaphylaxis - immunology Anti-Inflammatory Agents - adverse effects anti-infliximab antibodies Antibodies, Anti-Idiotypic - blood Antibodies, Anti-Idiotypic - immunology Antibodies, Monoclonal - adverse effects Biological and medical sciences Dermatology drug allergy Drug Hypersensitivity - blood Drug Hypersensitivity - immunology drug-specific IgE and IgM Enzyme-Linked Immunosorbent Assay Female Fundamental and applied biological sciences. Psychology Fundamental immunology Humans Immunoglobulin E - blood Immunoglobulin E - immunology Immunoglobulin M - blood Immunoglobulin M - immunology Immunoglobulins Infliximab Male Medical sciences Middle Aged Monoclonal antibodies Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis Skin Tests |
| title | Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T19%3A49%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Anti-infliximab%20IgE%20and%20non-IgE%20antibodies%20and%20induction%20of%20infusion-related%20severe%20anaphylactic%20reactions&rft.jtitle=Allergy%20(Copenhagen)&rft.au=Vultaggio,%20A&rft.date=2010-05&rft.volume=65&rft.issue=5&rft.spage=657&rft.epage=661&rft.pages=657-661&rft.issn=0105-4538&rft.eissn=1398-9995&rft.coden=LLRGDY&rft_id=info:doi/10.1111/j.1398-9995.2009.02280.x&rft_dat=%3Cproquest_cross%3E2004716031%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=196904656&rft_id=info:pmid/19951375&rfr_iscdi=true |